Biochem/physiol Actions

Cell permeable: no

Reversible: no

Product does not compete with ATP.

Primary TargetPTEN

General description

A potent protein phosphotyrosine phosphatase inhibitor and insulin receptor kinase (IRK) activator. Excellent insulin mimetic at 15 µg/kg in vitro and in vivo for use. Inhibits the in situ dephosphorylation of autophosphorylated insulin receptors with over 1000-fold greater potency than sodium orthovanadate. Arrests proliferation of neuroblastoma NB 41 and glioma C6 cells at the G₂/M transition of the cell cycle. Also reported to potently inhibit PTEN (IC₅₀ = 38 nM).

A potent insulin receptor kinase (IRK) activator and protein phosphotyrosine phosphatase inhibitor. Excellent insulin mimetic for in vitro and in vivo use (15 µg/kg). Inhibits in situ dephosphorylation of autophosphorylated insulin receptors with greater than 1000-fold potency over sodium orthovanadate. Arrests proliferation of neuroblastoma NB 41 and glioma C6 cells at the G₂/M transition of the cell cycle. Also reported to potently inhibit PTEN (IC₅₀ = 38 nM). The water content varies from lot to lot and is supplied on the label along with the lot-specific molecular weight.

The water content varies from lot to lot and is supplied on the label along with the lot-specific molecular weight.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Schmid, A.C., et al. 2004. FEBS Lett.566, 35.Muzyamba, M.C., et al. 1999. J. Physiol. 517, 421.Drake, P.G., et al. 1996. Endocrinology137, 4960.Bevan, A.P., et al. 1995. Am. J. Physiol.268, E60.Bevan, A.P., et al. 1995. J. Biol. Chem. 270, 10784.Yale, J.F., et al. 1995. Diabetes 44, 1274.Posner, B.I., et al. 1994. J. Biol. Chem. 269, 4596.

Packaging

Packaged under inert gas

10 mg in Plastic ampoule

Reconstitution

Unstable in solution; reconstitute just prior to use.

Warning

Toxicity: Standard Handling (A)